Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WDR5 | P61964 | 1/20 | 0.32 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.32 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MMP14 | P50281 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13855834 | 0.80 | AKR1C2 (0.32) | WDR5AKR1C2AKR1C1 | |
| SCHEMBL17744442 | 0.77 | GAA (0.41) | THRBGAAMMP14 | |
| SCHEMBL17744493 | 0.77 | AKR1C2 (0.32) | WDR5AKR1C2AKR1C1THRB | |
| SCHEMBL17744568 | 0.74 | GPR35 (0.43) | — | |
| SCHEMBL17744451 | 0.74 | GAA (0.34) | THRBGAAMMP14 | |
| SCHEMBL17744267 | 0.71 | GAA (0.39) | THRBGAAMMP14 | |
| SCHEMBL29344158 | 0.70 | HSD17B10 (0.37) | AKR1C2AKR1C1 | |
| SCHEMBL8489664 | 0.70 | AKR1C2 (0.43) | WDR5AKR1C2AKR1C1THRBGAA | |
| SCHEMBL24512726 | 0.70 | HSD17B10 (0.44) | AKR1C2AKR1C1THRB | |
| SCHEMBL26231908 | 0.70 | WDR5 (0.35) | WDR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3020718-B1 | NOVEL PDE4 INHIBITOR | MEIJI SEIKA PHARMA CO LTD (JP) | 2018-12-26 | — | — | EP | disclosed |
| US-9890142-B2 | PDE4 inhibitor | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2018-02-13 | — | — | US | disclosed |
| US-9850235-B2 | — | — | 2017-12-26 | — | — | US | disclosed |
| US-20160159783-A1 | PDE4 Inhibitor | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2016-06-09 | — | — | US | disclosed |
| EP-3020718-A1 | NOVEL PDE4 INHIBITOR | Meiji Seika Pharma Co., Ltd. (JP) | 2016-05-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159783-A1 | PDE4 Inhibitor | PDE4A, PDE4B, PDE3B | WDR5 2943/4885AKR1C2 627/4885AKR1C1 507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.